Piper Jaffray analyst Charles Duncan reiterated an Overweight rating and boosted his price target on Threshold Pharmaceuticals (NASDAQ: THLD) to $15.00 (from $13.00) saying a Hypoxia driven pipeline could emerge in 2015.
Duncan commented, "We recently caught up with Threshold because we believe 2015 could prove transformational for the company. Due to 2015 likely yielding multiple pivotal trial readouts and increased visibility on a wholly-owned but as yet under the radar-screen program that could take a run at higher profile TKi lung cancer programs, we would now include THLD as a top-pick small cap, under-discovered OncoInnovator. The key events of note in 2015 may be data (event driven) from the Phase IIIs for TH-302 in soft tissue sarcoma (STS) and pancreatic cancer. These are likely YE15 or early-'16 events but recent data in STS enhance our conviction that the study design could result in approvable and clinically significant benefit of 25-35% increased OS in this SPA-backed trial."
For an analyst ratings summary and ratings history on Threshold Pharmaceuticals click here. For more ratings news on Threshold Pharmaceuticals click here.
Shares of Threshold Pharmaceuticals closed at $3.52 yesterday.
He gets two cents for each negative post he writes...The fact that some of the posts have correct spelling and grammar is outstanding. We all (fellow doctors at the his home) are so proud of all the progress he has made.
Go Johnny, Go.
You asked me if I was green or Red. Excuse me for providing context to your question...My comments to you on this board are made because you simply add no value to the conversation. You are simply negative on Rnn for the sake of being Negative. Your conclusions have to fact based thesis around them...Just random thoughts racing through that whole in your head. Have fun in S. California I just got back. Stayed at the Marriott in Anaheim. I'm done as you are boring me now...Best to all longs.
I sold out my 55,000 common at an avg. cost of $1.56. Started my new position at 1.02/ through .67. My avg. cost is .79 PPS. Your statement of you don't take people seriously if they stated their positions is with out a doubt the dumbest thing you have stated.
Very funny action...We are so controlled by the big boys...
Maybe? However, if you mix a secondary with some good news/results and etc...the effect can be positive. I've bought plenty of bio's at the 1.50 pps secondary price and watch them roll up to 6.00/7.00 pps. Best.
And Toppy, seek help...
I told the board on last Thursday...She's about to blow upwards. OPXA another reasonable spec (risk/reward).
As for Toppy, he's simply lying like a crazy man in NY on the the street.
Roth Capital affirms GenVec (Nasdaq: GNVC) at Buy with a price target of $8 following a recent update from management.
Analyst Joseph Pantginis sees 2015 as being a potentially transformative year for GenVec. The analyst commented, GenVec has been running lean operations with two primary ongoing activities:
1) providing background support to Novartis for the hearing loss program; and
2) continuing its internal efforts to progress and potentially monetize its proprietary adenoviral platform, namely vaccine candidates.
Pantginis continued, We believe 2015 could be quite an interesting year for GenVec. For the NVS hearing loss program media attention and importantly, focus on the Novartis website continue to fuel excitement in the program in our belief. With patients already having been dosed we are now entering a time where NVS is deciding how to show its hand should any efficacy be seen. Recall the doses being used are thought to be therapeutic based on animal model data. The balancing act being played revolves around announcing transformational data for hearing loss and building a robust data set for future regulatory filings (if successful).
For an analyst ratings summary and ratings history on GenVec, Inc. click here. For more ratings news on GenVec, Inc. click here.
GenVec, Inc. closed at $3.55 yesterday.
Bid and Ask now with-in a penny. We are in the 90 percent chance of moving out and taking out our 52 week high. Next week should be fun. Gale/Rnn all looking good.
My guess..... .96. Next week we dump the shorts and Toppy for good.
If you know how to read a chart you can see...we are not even close to the end of this run up-warded in our PPS. Sell? The only ones here trying to get you to sell your shares here are Toppy and the rest of the paid short bashes. Best to longs...And you still have a chance with Gnvc and it makes its why to its 52week high next week.
Tell that to the other billion dollar Bio's who haven't or are just in phase 111 drug trials. Now that's probably the most ignorant statement you've made so far...And that is saying something. You should go over to Gnvc and short that stock too. I've made close to 70% and still holding in 2015. Over 41 patents held there and a partnership is in the making.
The chart and volume tells us we are moving much higher...We will make a big run for the 52 week high next week. Currently, the small pullback will allow the MM's to catch up and consolidated the stock before the big run up. And if that comes we could easly be looking at a $6-8 PPS once the 52 week high is taken out.
Best to all longs....Rnn, opxa, Thld all moving nicely in 2015.
A nice move to .90 and the fight to a $1.00 next. Hope you all look at Gnvc as it looks like a complete Break-out at hand.
Picks for this year...Bought gale 1.50, long Dara .77, long opxa .75, long Thld @2.80, Ambs @ .078, long Gnvc @ 2.25. Best to longs...
Looking for a move above $5 PPS soon. GL longs
At least we won't see you on these boards anymore....
Up 15% and shorts can't be found....